Executive Brief

News Report

The News: FDA grants accelerated approval to datopotamab deruxtecan for EGFR-mutated NSCLC.
Clinical Win: This approval provides a new treatment option for patients with limited alternatives.
Target Specialty: Oncology

Key Data at a Glance

Overall Response Rate: 45%
Duration of Response: 6.5 months
Patient Population: 114 patients with EGFR-mutated NSCLC

The FDA announced on June 23, 2025, the accelerated approval of datopotamab deruxtecan-dlnk (Datroway) for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This approval is significant as it provides a new treatment option for a patient population with limited alternatives following standard therapies.

Clinical Context

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide, with a significant proportion of cases harboring mutations in the EGFR gene. These mutations lead to aberrant signaling pathways that promote tumor growth and survival. Current treatment strategies for EGFR-mutated NSCLC typically involve targeted therapies, but resistance often develops, necessitating alternative therapeutic approaches. Datopotamab deruxtecan-dlnk is an antibody-drug conjugate designed to target and deliver cytotoxic agents directly to cancer cells expressing the Trop-2 protein, which is often overexpressed in various solid tumors, including NSCLC. The approval of this drug marks an important advancement in the treatment landscape for patients who have progressed on prior therapies, potentially improving outcomes in this challenging patient population.

Key Findings

The FDA granted accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated NSCLC based on data from two clinical trials: TROPION-Lung05 and TROPION-Lung01, which included a pooled subgroup of 114 patients who had received prior treatment with EGFR-directed therapy and platinum-based chemotherapy [2].

The overall response rate (ORR) was 45% (95% CI: 35, 54), indicating a meaningful level of efficacy in this heavily pre-treated population [2].

The median duration of response (DOR) was reported at 6.5 months (95% CI: 4.2, 8.4) [2].

Safety & Tolerability

The recommended dosage for datopotamab deruxtecan-dlnk is 6 mg/kg administered as an intravenous infusion every three weeks until disease progression or unacceptable toxicity [2].
Clinicians should consult current prescribing information for full dosing guidance.

What This Means for Clinical Practice

Datopotamab deruxtecan-dlnk offers a new option for oncologists treating patients with EGFR-mutated NSCLC who have exhausted prior therapies. The 45% ORR suggests that a significant subset of patients may benefit from this treatment, potentially leading to improved disease control. Clinicians should consider this therapy for eligible patients, particularly those who have not responded to previous treatments. Ongoing monitoring for adverse effects, including interstitial lung disease and ocular reactions, will be essential as part of the patient management strategy. As this treatment becomes integrated into practice, questions regarding its optimal sequencing with other therapies and long-term outcomes will need to be addressed in future studies.

Clinical Perspective

Workflow: Oncologists should integrate datopotamab deruxtecan into treatment plans for eligible patients with EGFR mutations.

Economics: The introduction of this therapy may impact healthcare costs associated with NSCLC management.

Patient Outcomes: Improved response rates could enhance patient quality of life and overall survival.

Dr. Rahul Verma, Oncology

FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC: 45% ORR in Prior Therapy Patients

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Oncology in your inbox.

Related Drug Updates

Zanubrutinib and Acalabrutinib: New Treatment Paradigms for Mantle Cell Lymphoma

FDA Panel Votes Against Camizestrant for ESR1-Mutated HR-Positive Breast Cancer

Zanubrutinib and Sonrotoclax Update Treatment Algorithm for Mantle Cell Lymphoma

Verified HCP Portal